Back to Journals » Biologics: Targets and Therapy » Volume 9

Giant-cell tumor of bone: treatment options and role of denosumab

Authors Singh A, Chawla N, Chawla SP

Received 6 March 2015

Accepted for publication 5 May 2015

Published 14 July 2015 Volume 2015:9 Pages 69—74

DOI https://doi.org/10.2147/BTT.S57359

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Doris Benbrook


Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2

1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA

Abstract: Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.

Keywords: denosumab, giant-cell tumor of bone, sarcoma, targeted therapy, RANKL
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]